Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer

J. M. Blazeby, T. Conroy, E. Hammerlid, Peter Fayers, O. Sezer, J. I. Arraras, M. Koller, A. Bottomley, C. W. Vickery, P. L. Etienne, D. Alderson, on behalf of the European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups

Research output: Contribution to journalArticle

216 Citations (Scopus)

Abstract

Quality of life (QOL) assessment requires clinically relevant questionnaires that yield accurate data. This study defined measurement properties and the clinical validity of the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess QOL in oesophageal cancer. The oesophageal module the QLQ-OES24 and core questionnaire, the Quality of Life-Core 30 questionnaire (QLQ-C30) was administered patients undergoing treatment with curative (n = 267) or palliative intent (n = 224) and second assessments performed 3 months or 3 weeks later respectively. Psychometric tests examined scales and measurement properties of the module. Questionnaires were well accepted, compliance rates were high and less than 2% of items had missing data. Multi-trait scaling analyses and face validity refined the module to four scales and six single items (QLQ-OES18). Selective scales distinguished between clinically distinct groups of patients and demonstrated treatment-induced changes over time. The EORTC QLQ-OES18 demonstrates good psychometric and clinical validity. It is recommended for use with the core questionnaire, the QLQ-C30, to assess QOL in patients with oesophageal cancer. (C) 2003 Elsevier Science Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)1384-1394
Number of pages10
JournalEuropean Journal of Cancer
Volume39
Issue number10
DOIs
Publication statusPublished - Jul 2003

Keywords

  • quality of life
  • oesophageal cancer
  • questionnaires
  • QLQ-OES18
  • QLQ-C30
  • validation
  • oesophagectomy
  • chemotherapy
  • stents
  • randomised trial
  • malignant dysphagia
  • chemptherapy
  • surgery
  • instrument
  • CISPLATIN
  • resection
  • carcinoma
  • therapy

Cite this

Blazeby, J. M., Conroy, T., Hammerlid, E., Fayers, P., Sezer, O., Arraras, J. I., ... on behalf of the European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups (2003). Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. European Journal of Cancer, 39(10), 1384-1394. https://doi.org/10.1016/S0959-8049(03)00270-3

Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. / Blazeby, J. M.; Conroy, T.; Hammerlid, E.; Fayers, Peter; Sezer, O.; Arraras, J. I.; Koller, M.; Bottomley, A.; Vickery, C. W.; Etienne, P. L.; Alderson, D.; on behalf of the European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups.

In: European Journal of Cancer, Vol. 39, No. 10, 07.2003, p. 1384-1394.

Research output: Contribution to journalArticle

Blazeby, JM, Conroy, T, Hammerlid, E, Fayers, P, Sezer, O, Arraras, JI, Koller, M, Bottomley, A, Vickery, CW, Etienne, PL, Alderson, D & on behalf of the European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups 2003, 'Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer', European Journal of Cancer, vol. 39, no. 10, pp. 1384-1394. https://doi.org/10.1016/S0959-8049(03)00270-3
Blazeby, J. M. ; Conroy, T. ; Hammerlid, E. ; Fayers, Peter ; Sezer, O. ; Arraras, J. I. ; Koller, M. ; Bottomley, A. ; Vickery, C. W. ; Etienne, P. L. ; Alderson, D. ; on behalf of the European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups. / Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. In: European Journal of Cancer. 2003 ; Vol. 39, No. 10. pp. 1384-1394.
@article{bbb0b4c3608d4cfbaa6a6e58a14d4a00,
title = "Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer",
abstract = "Quality of life (QOL) assessment requires clinically relevant questionnaires that yield accurate data. This study defined measurement properties and the clinical validity of the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess QOL in oesophageal cancer. The oesophageal module the QLQ-OES24 and core questionnaire, the Quality of Life-Core 30 questionnaire (QLQ-C30) was administered patients undergoing treatment with curative (n = 267) or palliative intent (n = 224) and second assessments performed 3 months or 3 weeks later respectively. Psychometric tests examined scales and measurement properties of the module. Questionnaires were well accepted, compliance rates were high and less than 2{\%} of items had missing data. Multi-trait scaling analyses and face validity refined the module to four scales and six single items (QLQ-OES18). Selective scales distinguished between clinically distinct groups of patients and demonstrated treatment-induced changes over time. The EORTC QLQ-OES18 demonstrates good psychometric and clinical validity. It is recommended for use with the core questionnaire, the QLQ-C30, to assess QOL in patients with oesophageal cancer. (C) 2003 Elsevier Science Ltd. All rights reserved.",
keywords = "quality of life, oesophageal cancer, questionnaires, QLQ-OES18, QLQ-C30, validation, oesophagectomy, chemotherapy, stents, randomised trial, malignant dysphagia , chemptherapy, surgery, instrument, CISPLATIN, resection, carcinoma, therapy",
author = "Blazeby, {J. M.} and T. Conroy and E. Hammerlid and Peter Fayers and O. Sezer and Arraras, {J. I.} and M. Koller and A. Bottomley and Vickery, {C. W.} and Etienne, {P. L.} and D. Alderson and {on behalf of the European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups}",
year = "2003",
month = "7",
doi = "10.1016/S0959-8049(03)00270-3",
language = "English",
volume = "39",
pages = "1384--1394",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "ELSEVIER APPL SCI PUBL LTD",
number = "10",

}

TY - JOUR

T1 - Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer

AU - Blazeby, J. M.

AU - Conroy, T.

AU - Hammerlid, E.

AU - Fayers, Peter

AU - Sezer, O.

AU - Arraras, J. I.

AU - Koller, M.

AU - Bottomley, A.

AU - Vickery, C. W.

AU - Etienne, P. L.

AU - Alderson, D.

AU - on behalf of the European Organisation for Research and Treatment of Cancer Gastrointestinal and Quality of Life Groups

PY - 2003/7

Y1 - 2003/7

N2 - Quality of life (QOL) assessment requires clinically relevant questionnaires that yield accurate data. This study defined measurement properties and the clinical validity of the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess QOL in oesophageal cancer. The oesophageal module the QLQ-OES24 and core questionnaire, the Quality of Life-Core 30 questionnaire (QLQ-C30) was administered patients undergoing treatment with curative (n = 267) or palliative intent (n = 224) and second assessments performed 3 months or 3 weeks later respectively. Psychometric tests examined scales and measurement properties of the module. Questionnaires were well accepted, compliance rates were high and less than 2% of items had missing data. Multi-trait scaling analyses and face validity refined the module to four scales and six single items (QLQ-OES18). Selective scales distinguished between clinically distinct groups of patients and demonstrated treatment-induced changes over time. The EORTC QLQ-OES18 demonstrates good psychometric and clinical validity. It is recommended for use with the core questionnaire, the QLQ-C30, to assess QOL in patients with oesophageal cancer. (C) 2003 Elsevier Science Ltd. All rights reserved.

AB - Quality of life (QOL) assessment requires clinically relevant questionnaires that yield accurate data. This study defined measurement properties and the clinical validity of the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess QOL in oesophageal cancer. The oesophageal module the QLQ-OES24 and core questionnaire, the Quality of Life-Core 30 questionnaire (QLQ-C30) was administered patients undergoing treatment with curative (n = 267) or palliative intent (n = 224) and second assessments performed 3 months or 3 weeks later respectively. Psychometric tests examined scales and measurement properties of the module. Questionnaires were well accepted, compliance rates were high and less than 2% of items had missing data. Multi-trait scaling analyses and face validity refined the module to four scales and six single items (QLQ-OES18). Selective scales distinguished between clinically distinct groups of patients and demonstrated treatment-induced changes over time. The EORTC QLQ-OES18 demonstrates good psychometric and clinical validity. It is recommended for use with the core questionnaire, the QLQ-C30, to assess QOL in patients with oesophageal cancer. (C) 2003 Elsevier Science Ltd. All rights reserved.

KW - quality of life

KW - oesophageal cancer

KW - questionnaires

KW - QLQ-OES18

KW - QLQ-C30

KW - validation

KW - oesophagectomy

KW - chemotherapy

KW - stents

KW - randomised trial

KW - malignant dysphagia

KW - chemptherapy

KW - surgery

KW - instrument

KW - CISPLATIN

KW - resection

KW - carcinoma

KW - therapy

U2 - 10.1016/S0959-8049(03)00270-3

DO - 10.1016/S0959-8049(03)00270-3

M3 - Article

VL - 39

SP - 1384

EP - 1394

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -